BUFFALO, NY--(Marketwired - Apr 1, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced two upcoming poster presentations at the 2014 American Association for Cancer Research (AACR) Annual Meeting, April 5-9, 2014 in San Diego, CA. 

The posters, titled "Synergistic effects of CBL0137 and gemcitabine against non-small cell lung and pancreatic cancer xenografts" and "CBL0137 demonstrates significant antitumor activity against hepatocellular carcinoma alone and in combination with sorafenib" will be presented on Sunday, April 6, during the Experimental and Molecular Therapeutics sessions 5 and 6, respectively. Both posters describe preclinical studies with Curaxin CBL0137, a drug candidate in clinical development as a cancer therapy.

Intravenous administration of CBL0137 is being evaluated in a Phase 1 trial with patients with metastatic or unresectable advanced solid cancers and lymphomas. Oral administration of CBL0137 is being assessed in a Phase 1 study of patients with advanced solid tumors that are resistant or refractory to current standard treatment. To date, no drug-related serious adverse events have been reported in either trial. 

For more information, please visit the AACR Annual Meeting 2014 home page at:

About Cleveland BioLabs
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's lead product candidates are Entolimod, which is being developed as radiation countermeasure and a potential cancer treatment and Curaxin CBL0137, our lead oncology product candidate. CBL0137 is under development by Incuron, LLC, a Russian Federation based joint venture founded in 2010 between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures," and Cleveland BioLabs. Cleveland BioLabs, Inc. conducts business in the United States and in the Russian Federation through its wholly and majority owned operating subsidiaries. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children's Cancer Institute Australia for Medical Research. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com. To learn more about Incuron, LLC, please visit the company's website at http://www.incuron.com/.

This press release contains certain forward-looking information about Cleveland BioLabs that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the likelihood of receiving funding; our ability to successfully develop and commercialize our therapeutic products; the conduct and results of our various clinical trials; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. 

These factors include, among others, the decisions of third parties regarding whether or not to fund the Company through grants; the Company's failure to successfully and timely develop existing and new products; the Company's collaborative relationships and the financial risks related thereto; the Company's inability to obtain regulatory approval in a timely manner or at all; the risks inherent in the early stages of drug development and in conducting clinical trials; the Company's ability to comply with its obligations under license agreements; the Company's history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the Company's periodic filings with the Securities and Exchange Commission.